Rational use of drug-eluting stents: a comparison of different policies.
Long-term results of recent landmark trials document both benefits and risks of drug-eluting stents (DES) for coronary revascularization. Interestingly, the conclusions drawn from these data vary widely since significant differences in DES penetration rates become obvious when the utilization of this technology is compared between hospitals or even countries. Based on the recommendations of the European Society of Cardiology, the FDA as well as data derived from the BASKET-LATE study, we propose that a maximum penetration rate of 50% for DES seems appropriate at present. Analysis of the length/diameter distribution combined with the use of validated restenosis reference charts allows identification of high-risk patients regarding restenosis risk and modeling the use of DES depending on financial resources and clinical indication. Such algorithm provides the rational for preprocedural risk stratification and efficient use of resources.
Medical Clinic II, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Marko
M
Remmel
Franz
F
Hartmann
Lars C
LC
Harland
Heribert
H
Schunkert
Peter W
PW
Radke
D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects / Q000191:economics
D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus